[HTML][HTML] Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure
BB Das - Medicina, 2024 - mdpi.com
This review article examines the mechanism of action of Angiotensin Receptor–Neprilysin
Inhibitors (ARNIs) and Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2is) in managing …
Inhibitors (ARNIs) and Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2is) in managing …
[引用][C] What's new in heart failure? June–July 2024
settings. A total of 1003 participants were examined, including 174 inpatients with acute HF,
172 outpatients with chronic HF, and 786 control subjects (elective patients attending …
172 outpatients with chronic HF, and 786 control subjects (elective patients attending …
[引用][C] The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: Is the time ripe for clinical use of sodium–glucose cotransporter 2 …
A Porcari, M Fontana - European Journal of Heart Failure, 2024 - Wiley Online Library
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively common cause of heart
failure (HF) that results from accumulation of amyloid, derived from transthyretin (TTR), a …
failure (HF) that results from accumulation of amyloid, derived from transthyretin (TTR), a …